CGTX
Cognition Therapeutics, Inc.NASDAQHealthcare$0.87-2.63%ClosedMarket Cap: $63.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.17
P/S
0.00
EV/EBITDA
-0.75
DCF Value
$0.61
FCF Yield
-39.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-104.3%
ROA
-48.5%
ROIC
-136.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-13.7M | $-3.3M | $-0.04 | — |
| FY 2025 | $0.00 | -Infinity% | $-47.8M | $-23.5M | $-0.32 | — |
| Q3 2025 | $0.00 | -Infinity% | $-6.4M | $-4.9M | $-0.06 | — |
| Q2 2025 | $0.00 | NaN% | $-14.0M | $-6.7M | $-0.11 | — |
| Q1 2025 | $0.00 | NaN% | $-13.8M | $-8.5M | $-0.14 | — |
| Q4 2024 | $0.00 | NaN% | $-10.7M | $-7.8M | $-0.17 | — |
| FY 2024 | $0.00 | NaN% | $-54.0M | $-34.0M | $-0.85 | — |
| Q3 2024 | $0.00 | NaN% | $-14.5M | $-9.9M | $-0.25 | — |
| Q2 2024 | $0.00 | NaN% | $-14.7M | $-7.0M | $-0.18 | — |
| Q1 2024 | $0.00 | -Infinity% | $-14.1M | $-9.2M | $-0.27 | — |
| Q4 2023 | $0.00 | NaN% | $-15.2M | $-8.1M | $-0.26 | — |
| FY 2023 | $0.00 | NaN% | $-50.7M | $-25.8M | $-0.86 | — |